Anticancer drug therapy in the older cancer patient: Pharmacology and polypharmacy

Current Treatment Options in Oncology

Volumn 9, Issue 2-3, 2008, Pages 191-203

  Lichtman, Stuart M ^a   Boparai, Manpreet K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN DERIVATIVE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; FLUDARABINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; HYDROXYUREA; LEVAMISOLE; LIPOSOMAL ANTHRACYCLINE; MELPHALAN; METHOTREXATE; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; PURINE DERIVATIVE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID; VINCRISTINE;

AGE; AGED; ALOPECIA; ANAMNESIS; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVOR; CARDIOMYOPATHY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; COMORBIDITY; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FUNCTIONAL STATUS; HAND FOOT SYNDROME; HUMAN; KIDNEY FUNCTION; LEUKOPENIA; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT PARTICIPATION; PATIENT SELECTION; PROSTATE CANCER; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION;

AGED; AGING; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PATIENT COMPLIANCE; POLYPHARMACY; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 58149097469     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-008-0060-6     Document Type: Article

References (61)

1. Venook AP, Egorin MJ, Rosner GL, et al.: Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000, 18:2780-2787
2. Venook AP, Enders Klein C, Fleming G, et al.: A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 2003;14:1783-1790, doi: 10.1093/annonc/mdg493
3. Smith TJ, Khatcheressian J, Lyman GH, et al.: 2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-3205
4. Launay-Vacher V, Oudard S, Janus N, et al.: Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: The renal insufficiency and anticancer medications (IRMA) study. Cancer 2007;110:1376-1384, doi: 10.1002/cncr.22904
5. Lichtman SM, Wildiers H, Launay-Vacher V, et al.: International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007;43:14-34
6. Launay-Vacher V, Chatelut E, Lichtman S, et al.: Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol, 2007, 18, 1314-1321
7. National Comprehensive Cancer Network: Senior Adult Oncology. 2007, www.nccn.org accessed March 29, 2008
8. Vigneau C, Ardiet C, Bret M, et al.: Intermediate-dose (25 mg/m 2) IV melphalan for multiple myeloma with renal failure. J Nephrol 2002;15:684-689
9. Jantunen E, Kuittinen T, Penttila K, et al.: High-dose melphalan (200 mg/m 2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: Comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006;37:917-922
10. Stein BN, Petrelli NJ, Douglass HO, et al.: Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995;75:11-17
11. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 16:3537-3541, 1998
12. Sargent DJ, Goldberg RM, Jacobson SD, et al.: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091-1097
13. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al.: Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085-4091
14. Haller DG, Catalano PJ, Macdonald JS, et al.: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage ii and iii colon cancer: Final report of Intergroup 0089. J Clin Oncol 23:8671-8678, 2005
15. Schrag D, Cramer LD, Bach PB, et al.: Age and adjuvant chemotherapy use after surgery for stage iii colon cancer. J Natl Cancer Inst 2001;93:850-857
16. Folprecht G, Cunningham D, Ross P, et al.: Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: A pooled analysis of clinical trials. Ann Oncol 2004;15:1330-1338
17. Cassidy J, Twelves C, Cameron D, et al.: Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 1999;44:453-460
18. Twelves C, Wong A, Nowacki MP, et al.: Capecitabine as adjuvant treatment for stage iii colon cancer. N Engl J Med 2005;352:2696-2704
19. Feliu J, Escudero P, Llosa F, et al.: Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: An oncopaz cooperative group study. J Clin Oncol 2005;23:3104-3111
20. Takimoto CH, Remick SC, Sharma S, et al.: Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: A National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol 2003;21:2664-2672
21. Aparicio T, Desrame J, Lecomte T, et al.: Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer 2003;89:1439-1444
22. Feliu J, Salud A, Escudero P, et al.: XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006;94:969-975
23. Langer CJ, Manola J, Bernardo P, et al.: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of eastern cooperative oncology group 5592, a randomized trial. J Natl Cancer Inst 2002;94:173-181
24. Calvert AH, Egorin MJ: Garboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. Eur J Cancer 2002;38:11-16
25. Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003;97:2869-2879
26. Dees EC, O'Reilly S, Goodman SN, et al.: A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000;18:521-529
27. Safra T, Muggia F, Jeffers S, et al.: Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m 2. Ann Oncol 2000;11:1029-1033
28. Tannock IF, de Wit R, Berry WR, et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512
29. Wong M, Balleine RL, Blair EY, et al.: Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol 2006;24:2448-2455
30. Lichtman SM, Hollis D, Miller AA, et al.: Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol 2006;24:1846-1851
31. Smorenburg CH, ten Tije AJ, Verweij J, et al.: Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer 2003;39:196-202
32. Seidman AD, Berry D, Cirrincione C, et al.: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008;26:1642-1649
33. Hurria A, Fleming MT, Baker SD, et al.: Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 2006;12:6100-6105
34. Lichtman SM, Etcubanas E, Budman DR, et al.: The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: A prospective dose adjustment study. Cancer Invest 2002;20:904-913
35. Martell RE, Peterson BL, Cohen HJ, et al.: Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: A CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol 2002;50:37-45
36. Launay-Vacher V, Karie S, Deray G: GPR® Anticancéreux. Guide de prescription des médicaments chez le patient insuffisant renal (ed 3ème). Paris, Méditions International, 2005
37. Mita AC, Sweeney CJ, Baker SD, et al.: Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 2006;24:552-562
38. Weiss GJ, Langer C, Rosell R, et al.: Elderly patients benefit from second-line cytotoxic chemotherapy: A subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:4405-4411
39. O'Reilly S, Armstrong DK, Grochow LB: Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan [letter]. Gynecol Oncol 1997;67:329-330
40. Armstrong DK: Topotecan dosing guidelinesRin ovarian cancer: reduction and management of hematologic toxicity. Oncologist 2004;9:33-42
41. Fuchs CS, Moore MR, Harker G, et al.: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003;21:807-814
42. Miller AA, Rosner GL, Ratain MJ, et al.: Pharmacology of 21-day oral etoposide given in combination with i.v. Cisplatin in patients with extensive-stage small cell lung cancer: A Cancer and Leukemia Group B study (CALGB 9062). Clin Cancer Res 1997;3:719-725
43. Tan-Chiu E, Yothers G, Romond E, et al.: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-7819
44. Scappaticci FA, Skillings JR, Holden SN, et al.: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-1239
45. Jackman DM, Yeap BY, Lindeman NI, et al.: Phase II clinical trial of chemotherapy-naive patients >or= 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007;25:760-766
46. Fulton MM, Allen ER: PoAypharmacy in the elderly: a literature review. J Am Acad Nurse Pract 2005;17:123-132
47. Bergman-Evans B: AIDES to improving medication adherence in older adults. Geriatr Nurs 2006; 27:174-182; quiz 183
48. Burkhart PV, Sabate E: AdherEnce to long-term therapies: evidence for action. J Nurs Scholarsh 2003;35:207
49. Partridge AH, Avorn J, Wang PS, et al.: Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002;94:652-661
50. Cutting Edge Information: http://www.cuttingedgeinfo.com/ pharmapatientadherence/, accessed April 29, 2008
51. Tsang J, Rudychev I, Pescatore SL: Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM) [meeting abstracts]. J Clin oncol 2006, 24(Suppl 18): 6119
52. Partridge AH, LaFountain A, Mayer E, et al.: Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008;26:556-562
53. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 2005;353:487-497
54. Pugh MJ, Hanlon JT, Zeber JE, et al.: Assessing potentially inappropriate prescribing in the elderly Veterans Affairs population using the HEDIS 2006 quality measure. J Manag Care Pharm 2006;12:537-545
55. Hartigan K: PTtient education: the cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nurs 2003;7:21-24
56. Beers MH: Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 1997;157:1531-1536
57. Fick DM, Cooper JW, Wade WE, et al.: Updating the Beers criteria for potentially inappropriate medication use in older adults: Results of a US consensus panel of experts. Arch Intern Med 2003;163:2716-2724
58. Barry PJ, O'Keefe N, O'Connor KA, et al.: Inappropriate prescribing in the elderly: A comparison of the Beers criteria and the improved prescribing in the elderly tool (IPET) in acutely ill elderly hospitalized patients. J Clin Pharm Ther 2006;31:617-626
59. Cannon KT, Choi MM, Zuniga MA: Potentially inappropriate medication use in elderly patients receiving home health care: A retrospective data analysis. Am J Geriatr Pharmacother 2006;4:134-143
60. Budnitz DS, Shehab N, Kegler SR, et al.: Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007;147:755-765
61. Lichtman SM: Chemotherapy in the elderly. Semin Oncol 2004;31:160-174